Patent · US Active

Treatment for cerebral palsy gait impairment

US9408838B2 · kind B2 · utility

1Cited by

4References

23Claims

0Family size

Assignee

GILROSE PHARMACEUTICALS, LLC · US

Inventors

Bruce Roseman · White Plains, US
Gilla Kaplan · New York, US

Key dates

Filing date	Dec 16, 2015
Grant date	Aug 9, 2016
Priority date	—
Expiry date	Dec 16, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61B5/4064
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.